Real-time Estimate
Cboe BZX
02:32:12 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
2.295
USD
|
+1.10%
|
|
-5.42%
|
+54.37%
|
Fiscal Period: December |
2022
|
2024
|
---|
Capitalization
1 |
13.39
|
26.14
|
Enterprise Value (EV)
1 |
13.39
|
26.14
|
P/E ratio
|
-0.88
x
|
-2.39
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
2,789,916,667
x
|
-
|
EV / Revenue
|
2,789,916,667
x
|
-
|
EV / EBITDA
|
-
|
-
|
EV / FCF
|
-
|
-
|
FCF Yield
|
-
|
-
|
Price to Book
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,370
|
11,514
|
Reference price
2 |
1.600
|
2.270
|
Announcement Date
|
3/31/23
|
-
|
Fiscal Period: December |
2022
|
2024
|
---|
Net sales
|
0.0048
|
-
|
EBITDA
|
-
|
-
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
-8.154
|
-
|
Net margin
|
-169,877.29%
|
-
|
EPS
1 |
-1.810
|
-0.9500
|
Free Cash Flow
|
-
|
-
|
FCF margin
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
3/31/23
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
9.92
|
10
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
11.2
|
1.24
|
Leverage (Debt/EBITDA)
|
-3.843
x
|
-4.543
x
|
-
|
-
|
Free Cash Flow
|
-
|
-0.86
|
-3.41
|
-3.61
|
ROE (net income / shareholders' equity)
|
-
|
55.6%
|
2,320%
|
-99.8%
|
ROA (Net income/ Total Assets)
|
-
|
-173%
|
-36.8%
|
-48.8%
|
Assets
1 |
-
|
3.667
|
22.18
|
16.25
|
Book Value Per Share
2 |
-5.630
|
-5.900
|
1.320
|
0.5200
|
Cash Flow per Share
2 |
0.0300
|
0.5100
|
1.360
|
0.3000
|
Capex
1 |
0
|
-
|
0.22
|
0.02
|
Capex / Sales
|
-
|
-
|
4,580.2%
|
0.9%
|
Announcement Date
|
4/25/22
|
4/25/22
|
3/31/23
|
4/1/24
|
|
1st Jan change
|
Capi.
|
---|
| +54.37% | 26.14M | | -6.76% | 12.28B | | -5.68% | 8.05B | | +8.91% | 5.84B | | +27.21% | 5.66B | | -15.84% | 3.99B | | +10.70% | 2.7B | | -61.44% | 2.7B | | -6.99% | 2.39B | | +15.41% | 2.02B |
Diagnostic & Testing Substances
|